Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Total Current Liabilities (2020 - 2026)

Nautilus Biotechnology has reported Total Current Liabilities over the past 7 years, most recently at $8.3 million for Q1 2026.

  • Quarterly results put Total Current Liabilities at $8.3 million for Q1 2026, up 2.29% from a year ago — trailing twelve months through Mar 2026 was $8.3 million (up 2.29% YoY), and the annual figure for FY2025 was $8.0 million, up 4.19%.
  • Total Current Liabilities reached $8.3 million in Q1 2026 per NAUT's latest filing, up from $8.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $9.2 million in Q1 2024 and bottomed at $6.1 million in Q2 2022.
  • Median Total Current Liabilities over the past 5 years was $8.1 million (2025), compared with a mean of $8.0 million.
  • The largest annual shift saw Total Current Liabilities surged 256.02% in 2022 before it fell 16.33% in 2024.
  • Over 5 years, Total Current Liabilities stood at $6.8 million in 2022, then soared by 34.32% to $9.1 million in 2023, then decreased by 16.33% to $7.6 million in 2024, then grew by 4.19% to $8.0 million in 2025, then rose by 4.92% to $8.3 million in 2026.
  • Business Quant data shows Total Current Liabilities for NAUT at $8.3 million in Q1 2026, $8.0 million in Q4 2025, and $9.0 million in Q3 2025.